158 related articles for article (PubMed ID: 31933233)
1. Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe.
Madison T; Donner B; Mutter R; Mingrino R; Alvaro G
Pharmaceut Med; 2019 Oct; 33(5):395-406. PubMed ID: 31933233
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
Lem J; Younus M; Aram JA; Moosavi S; Freivogel K; Lewis A; Sobel RE
Pharmaceut Med; 2019 Apr; 33(2):121-133. PubMed ID: 31933256
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries.
von Bredow D; Toussi M; Samad A; Kaplan S; Domahidy M; de Voogd H; Böhmert S; Ramos RS; Arora D
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1385-1392. PubMed ID: 30379361
[TBL] [Abstract][Full Text] [Related]
4. Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once-weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour.
Lysen T; Karimi L; Wang M; Singh S; Toussi M
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5692. PubMed ID: 37661305
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and attitude of healthcare professionals toward medication pregnancy category systems in Saudi hospitals.
Alshammari TM; Alrwisan AA; Aljeraisy MI; Taher KW; Alissa FM; Mahmoud MA; Hassali MA; Aljadhey HS
Saudi Med J; 2014 Jul; 35(7):704-11. PubMed ID: 25028227
[TBL] [Abstract][Full Text] [Related]
6. Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.
de Vries ST; van der Sar MJM; Coleman AM; Escudero Y; Rodríguez Pascual A; Maciá Martínez MÁ; Cupelli A; Baldelli I; Šipić I; Andrić A; Michan L; Denig P; Mol PGM;
Drug Saf; 2018 Jul; 41(7):713-724. PubMed ID: 29500798
[TBL] [Abstract][Full Text] [Related]
7. The Awareness and Adherence of the Valproate Pregnancy Prevention Program: A Questionnaire Survey among Healthcare Professionals, Pharmacists, and Patients in Denmark.
Oliveri NMB; Hansen JM; Almarsdóttir AB; Jacobsen R
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767582
[TBL] [Abstract][Full Text] [Related]
8. Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
Sweeney C; Gilsenan A; Calingaert B; Moeller C; Schomakers G; Sok A; Holzmann R; Pisa F
Pharmaceut Med; 2024 Mar; 38(2):145-156. PubMed ID: 38296916
[TBL] [Abstract][Full Text] [Related]
9. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
Drug Saf; 2021 Feb; 44(2):193-209. PubMed ID: 33125664
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.
Mayall S; Kahlon R; Al-Dakkak I; Shen SW
Pharmaceut Med; 2021 Mar; 35(2):123-135. PubMed ID: 33660230
[TBL] [Abstract][Full Text] [Related]
11. Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk-minimization measures.
Salem L; Malouvier A; Blatchford J; Rivero-Ferrer E; Deltour N; Jacquot E
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1470-1479. PubMed ID: 31486198
[TBL] [Abstract][Full Text] [Related]
12. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
[TBL] [Abstract][Full Text] [Related]
13. Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis.
Artime E; Kahlon R; Méndez I; Kou T; Garrido-Estepa M; Qizilbash N
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):664-674. PubMed ID: 32394485
[TBL] [Abstract][Full Text] [Related]
14. Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.
de Vries ST; van der Sar MJM; Cupelli A; Baldelli I; Coleman AM; Montero D; Šipić I; Andrić A; Wennberg A; Ahlqvist-Rastad J; Denig P; Mol PGM;
Drug Saf; 2017 Aug; 40(8):729-742. PubMed ID: 28540672
[TBL] [Abstract][Full Text] [Related]
15. Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study.
Kaplan S; Patino O; Rainville C; Madison T
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):219-223. PubMed ID: 32914920
[TBL] [Abstract][Full Text] [Related]
16. Healthcare professionals' knowledge, attitude and acceptance of influenza vaccination in Saudi Arabia: a multicenter cross-sectional study.
Alshammari TM; Yusuff KB; Aziz MM; Subaie GM
BMC Health Serv Res; 2019 Apr; 19(1):229. PubMed ID: 30992004
[TBL] [Abstract][Full Text] [Related]
17. Knowledge of Adverse Drug Reaction Reporting Among Healthcare Professionals in Bhutan: A Cross-Sectional Survey.
Dorji C; Tragulpiankit P; Riewpaiboon A; Tobgay T
Drug Saf; 2016 Dec; 39(12):1239-1250. PubMed ID: 27743333
[TBL] [Abstract][Full Text] [Related]
18. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
O'Callaghan J; Griffin BT; Morris JM; Bermingham M
BioDrugs; 2018 Jun; 32(3):267-280. PubMed ID: 29721705
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study.
Landsberg W; Al-Dakkak I; Coppin-Renz A; Geis U; Peters-Strickland T; van Heumen E; Rahman M
Drug Saf; 2018 Aug; 41(8):797-806. PubMed ID: 29671224
[TBL] [Abstract][Full Text] [Related]
20. Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe.
Fife D; Waller J; Kaplan S; Hu P; Phillips S; Oliveria SA; Richarz U
Clin Drug Investig; 2019 Nov; 39(11):1057-1066. PubMed ID: 31325111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
